NT_1170x120_1-11-18

David Ricks

Lilly helping people prepare for disasters, making meds available

Lilly helping people prepare for disasters, making meds available

INDIANAPOLIS —  The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it’s critical to be prepared and ready to respond. That’s why Eli Lilly and Co. and two leading disaster relief organizations – Healthcare Ready and Direct Relief – are working to help people prepare for disasters and

Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

INDIANAPOLIS — Reinforcing their commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Co. announced it will introduce a lower-priced version of Humalog (insulin lispro injection 100 units/mL) in the United States — providing people with diabetes an insulin option that will have a list price 50 percent lower than the current

Eli Lilly earmarks funds for insulin facility upgrade

Eli Lilly earmarks funds for insulin facility upgrade

INDIANAPOLIS — Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. Eli Lilly said the investment will be used to replace a current insulin vial-filling line. The move also stands to enable the company to meet rising demand for its insulins — including Humalog

Eli Lilly to acquire CoLucid for $960 million

Eli Lilly to acquire CoLucid for $960 million

INDIANAPOLIS — Eli Lilly and Co. plans to buy CoLucid Pharmaceuticals Inc., maker of a promising migraine medication, for about $960 million in cash. Cambridge, Mass.-based CoLucid is currently in development with lasmiditan tablets, indicated for acute treatment of migraine, and has completed the first of two Phase 3 trials. A data read-out for the